For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Around that time, a doctor friend told him about ketamine for treatment-resistant depression. It wasn’t an FDA- approved treatment. But Winograd says it saved his life. But for every success s ...

As researchers and governments consider the therapeutic uses of psychedelics, Scott Marshall stands ready to supply them.

The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...

Starting today, people with Parkinson's disease will have a new treatment option, thanks to U.S. Food and Drug Administration approval of groundbreaking new technology.